0R15 8520.0 -2.3383% 0R1E 8203.0 -0.4731% 0M69 21090.0 67.5139% 0R2V 229.3078 10023.9647% 0QYR None None% 0QYP 417.4 -1.7882% 0RUK 2652.0 -9.2402% 0RYA 1520.0 -2.8754% 0RIH 174.55 -1.3563% 0RIH 175.396 0.4847% 0R1O 204.45 10097.0075% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 163.0 1.0194%
Last update at 2024-11-21T15:05:00Z
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Thu 17 Oct 24, 04:10 PMElanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement
Thu 10 Oct 24, 12:00 PMElanco Provides Update on Contract Manufacturing Partner
Fri 13 Sep 24, 11:30 AMBullish Elanco Animal Health Insiders Loaded Up On US$2.23m Of Stock
Fri 06 Sep 24, 04:05 PMElanco to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
Wed 28 Aug 24, 10:30 AMElanco Announces Credelio Quattro Moves to Final FDA Administrative Review
Tue 20 Aug 24, 10:27 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -66.00000M | -567.00000M | -672.00000M | 78.20M | 114.10M |
| Minority interest | - | - | - | - | - |
| Net income | -74.00000M | -472.00000M | -560.10000M | 67.90M | 86.50M |
| Selling general administrative | 1266.00M | 1404.00M | 996.60M | 760.20M | 735.20M |
| Selling and marketing expenses | - | - | 996.00M | - | - |
| Gross profit | 2505.00M | 2631.00M | 1606.70M | 1600.70M | 1493.00M |
| Reconciled depreciation | 528.00M | 556.00M | 516.90M | 314.50M | 296.00M |
| Ebit | 358.00M | 297.00M | 101.50M | 342.60M | 442.60M |
| Ebitda | 886.00M | 853.00M | 461.40M | 543.00M | 640.00M |
| Depreciation and amortization | 528.00M | 556.00M | 359.90M | 200.40M | 197.40M |
| Non operating income net other | -32.00000M | -5.00000M | 178.30M | -27.40000M | -41.30000M |
| Operating income | 358.00M | 297.00M | 101.50M | 342.60M | 313.80M |
| Other operating expenses | 4028.00M | 4463.00M | 3350.10M | 2701.00M | 2753.00M |
| Interest expense | 241.00M | 236.00M | 149.80M | 78.90M | 29.60M |
| Tax provision | 8.00M | -95.00000M | -111.90000M | 10.30M | 27.60M |
| Interest income | - | - | - | 78.90M | 29.60M |
| Net interest income | -241.00000M | -236.00000M | -149.80000M | -78.90000M | -29.60000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | 183.00M | 628.00M | 623.70M | 185.50M | 128.80M |
| Other items | - | - | - | - | - |
| Income tax expense | 8.00M | -95.00000M | -111.90000M | 10.30M | 27.60M |
| Total revenue | 4418.00M | 4765.00M | 3273.30M | 3071.00M | 3066.80M |
| Total operating expenses | 2115.00M | 2329.00M | 1683.50M | 1230.70M | 1179.20M |
| Cost of revenue | 1913.00M | 2134.00M | 1666.60M | 1470.30M | 1573.80M |
| Total other income expense net | -424.00000M | -864.00000M | -773.50000M | -264.40000M | -170.10000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -74.00000M | -472.00000M | -560.10000M | 67.90M | 86.50M |
| Net income applicable to common shares | -78.00000M | -472.00000M | -560.10000M | 67.90M | 86.50M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 15491.00M | 16483.00M | 17692.70M | 8985.80M | 8956.70M |
| Intangible assets | 4842.00M | 5587.00M | 6387.30M | 2482.80M | 2453.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 394.00M | 237.00M | 256.30M | 87.40M | 113.90M |
| Total liab | 8202.00M | 8945.00M | 9216.80M | 3438.90M | 3759.20M |
| Total stockholder equity | 7289.00M | 7538.00M | 8475.90M | 5546.90M | 5197.50M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 924.00M | 746.00M | 872.20M | 455.40M | 368.90M |
| Common stock | - | - | - | - | - |
| Capital stock | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Retained earnings | -1057.00000M | -949.00000M | -477.20000M | 84.30M | 16.40M |
| Other liab | 941.00M | 1150.00M | 1340.90M | 228.20M | 337.80M |
| Good will | 5993.00M | 6172.00M | 6224.80M | 2989.60M | 2958.00M |
| Other assets | 193.00M | 183.00M | 127.30M | 78.90M | 51.30M |
| Cash | 345.00M | 638.00M | 494.70M | 334.00M | 474.80M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1702.00M | 1643.00M | 2076.30M | 818.50M | 970.70M |
| Current deferred revenue | - | 185.00M | 148.60M | 116.00M | 367.60M |
| Net debt | 5491.00M | 5681.00M | 5632.20M | 2021.00M | 1997.50M |
| Short term debt | 388.00M | 294.00M | 554.50M | 24.50M | 29.00M |
| Short long term debt | 388.00M | 294.00M | 554.50M | 24.50M | 29.00M |
| Short long term debt total | 5836.00M | 6319.00M | 6126.90M | 2355.00M | 2472.30M |
| Other stockholder equity | 8738.00M | 8696.00M | 8650.10M | 5636.30M | 5403.30M |
| Property plant equipment | 999.00M | 1222.00M | 1316.30M | 1040.30M | 922.40M |
| Total current assets | 3279.00M | 3276.00M | 3416.50M | 2373.10M | 2504.90M |
| Long term investments | - | - | - | 21.10M | 15.30M |
| Net tangible assets | -3546.00000M | -4325.00000M | -4136.20000M | 74.50M | -265.30000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1002.00M | 1028.00M | 1076.70M | 889.90M | 709.40M |
| Long term debt | 5448.00M | 6025.00M | 5572.40M | 2330.50M | 2443.30M |
| Inventory | 1538.00M | 1373.00M | 1578.10M | 1050.70M | 1004.10M |
| Accounts payable | 390.00M | 418.00M | 501.00M | 222.60M | 205.20M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -392.00000M | -209.00000M | 303.00M | -173.70000M | -222.20000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -1057.00000M | -949.00000M | -477.20000M | 84.30M | 16.40M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 378.00M | 387.00M | 347.80M | 185.00M | 103.10M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 12212.00M | 13207.00M | 14276.20M | 6612.70M | 6451.80M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | 2330.50M | 2443.30M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -179.00000M | -530.00000M | 32.70M | -234.80000M | -127.00000M |
| Change to liabilities | -98.00000M | -120.00000M | 369.30M | -29.20000M | 116.10M |
| Total cashflows from investing activities | -179.00000M | -530.00000M | -4779.20000M | -234.80000M | -127.00000M |
| Net borrowings | -518.00000M | 241.00M | 3750.20M | -121.10000M | 2468.00M |
| Total cash from financing activities | -549.00000M | 210.00M | 4953.90M | -304.80000M | -35.20000M |
| Change to operating activities | -109.00000M | 31.00M | -122.90000M | 7.00M | -3.20000M |
| Net income | -78.00000M | -472.00000M | -560.10000M | 67.90M | 86.50M |
| Change in cash | -293.00000M | 132.00M | 160.30M | -332.40000M | 354.10M |
| Begin period cash flow | 638.00M | 506.00M | 345.10M | 677.50M | 323.40M |
| End period cash flow | 345.00M | 638.00M | 505.40M | 345.10M | 677.50M |
| Total cash from operating activities | 452.00M | 483.00M | -41.00000M | 224.10M | 487.30M |
| Issuance of capital stock | 0.00000M | 0.00000M | 1219.90M | 0.00000M | 1659.70M |
| Depreciation | 682.00M | 716.00M | 516.90M | 314.50M | 296.00M |
| Other cashflows from investing activities | -42.00000M | -8.00000M | -4677.30000M | -94.40000M | 7.50M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -269.00000M | 27.00M | -94.70000M | -33.10000M | -20.10000M |
| Change to account receivables | 14.00M | -3.00000M | 14.00M | -172.40000M | -122.00000M |
| Sale purchase of stock | - | - | 1219.90M | - | 1659.70M |
| Other cashflows from financing activities | 941.00M | 1033.00M | 4685.50M | -183.70000M | -1687.40000M |
| Change to netincome | 22.00M | 326.00M | -278.70000M | 36.80M | 13.50M |
| Capital expenditures | 184.00M | 197.00M | 310.90M | 197.40M | 134.50M |
| Change receivables | 14.00M | -25.00000M | 14.00M | -172.40000M | -122.00000M |
| Cash flows other operating | 179.00M | 434.00M | -7.70000M | 39.60M | 117.30M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -276.00000M | 163.00M | 133.70M | -315.50000M | 325.10M |
| Change in working capital | -462.00000M | -87.00000M | 165.70M | -227.70000M | -29.20000M |
| Stock based compensation | 59.00M | 66.00M | 47.70M | 49.40M | 26.00M |
| Other non cash items | 308.00M | 414.00M | -86.40000M | 19.90M | 168.70M |
| Free cash flow | 268.00M | 286.00M | -351.90000M | 26.70M | 352.80M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health |
-0.005 0.04% | 13.44 | - | 15.20 | 1.54 | 1.10 | 2.81 | -63.2812 |
| ZTS Zoetis Inc |
0.13 0.07% | 175.80 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.2 0.68% | 29.11 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 142.05 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.01 0.08% | 13.30 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.
2500 Innovation Way, Greenfield, IN, United States, 46140
| Name | Title | Year Born |
|---|---|---|
| Mr. Jeffrey N. Simmons | Pres, CEO & Director | 1967 |
| Mr. Todd S. Young | Exec. VP of Corp. Governance and Strategy & CFO | 1972 |
| Mr. Ramiro Martin Cabral | Exec. VP & Pres of Elanco International | 1972 |
| Mr. James M. Meer | Sr. VP & Chief Accounting Officer | 1970 |
| Mr. Chris Keeley | Sr. VP & Chief Information Officer | NA |
| Mr. David S. Kinard | Exec. VP of HR Corp. Affairs & Admin. | 1967 |
| Ms. Marcela A. Kirberger | Exec. VP, Gen. Counsel & Corp. Sec. | 1967 |
| Mr. David Alan Urbanek | Exec. VP of Manufacturing & Quality | 1967 |
| Mr. Shawn McKee | Sr. VP of U.S. Companion Animal | NA |
| Mr. Larbi Van Lier | Sr. VP of Asia | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...